Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine

Journal of Biomedical Science

Volumn 23, Issue 1, 2016, Pages

  Gableh, Fateme ^a   Saeidi, Mohsen ^a   Hemati, Shaghayegh ^b   Hamdi, Kasra ^c   Soleimanjahi, Hoorieh ^d   Gorji, Ali ^e,f   Ghaemi, Amir ^a,e,g  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

^e Shefa Neuroscience Research Center   (Iran)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Adjuvant combination; DNA vaccine; E7; Human Papilloma Virus; MPL; Galactosylceramide

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CANCER VACCINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; LIGAND; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR AGONIST; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; IMMUNOLOGICAL ADJUVANT; LIPID A; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; WART VIRUS; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; FEMALE; GALACTOSYLCERAMIDES; LIPID A; MICE; NEOPLASMS, EXPERIMENTAL; TOLL-LIKE RECEPTOR 4; VACCINES, DNA;

EID: 84955261926     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-016-0238-3     Document Type: Article

References (39)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-32. PubMed Epub 2007/04/04. eng.
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56. PubMed Epub 2010/10/19. eng.
3. Kumar S, Biswas M, Jose T. HPV vaccine: Current status and future directions. Med J Armed Forces India. 2015;71(2):171-7. PubMed Pubmed Central PMCID: PMC4388981, Epub 2015/04/11. eng.
4. Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice. J Virol Methods. 2014;206:12-8. PubMed Epub 2014/06/01. eng.
5. Tahamtan A, Ghaemi A, Gorji A, Kalhor HR, Sajadian A, Tabarraei A, et al. Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems. J Biomed Sci. 2014;21:69. PubMed Pubmed Central PMCID: PMC4237815, Epub 2014/08/01. eng.
6. Boyd D, Hung CF, Wu TC. DNA vaccines for cancer. IDrugs. 2003;6(12):1155-64. PubMed Epub 2003/12/11. eng.
7. Saeedi A, Ghaemi A, Tabarraei A, Moradi A, Gorji A, Semnani S, et al. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice. Virus Genes. 2014;49(1):11-21. PubMed Epub 2014/04/23. eng.
8. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008;4(6):449-52. PubMed Epub 2008/04/30. eng.
9. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood. 2007;110(6):2013-9. PubMed Pubmed Central PMCID: PMC1976361, Epub 2007/06/22. eng.
10. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med. 2007;204(11):2641-53. PubMed Pubmed Central PMCID: PMC2118481, Epub 2007/10/10. eng.
11. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One. 2009;4(2):e4384. PubMed Pubmed Central PMCID: PMC2634740, Epub 2009/02/07. eng.
12. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A. 2009;106(19):7962-7. PubMed Pubmed Central PMCID: PMC2674105, Epub 2009/05/07. eng.
13. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Drame M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine. 2009;27(45):6284-90. PubMed Epub 2009/10/27. eng.
14. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-20. PubMed Epub 2010/03/23. eng.
15. Ghaemi A, Sajadian A, Khodaie B, Lotfinia AA, Lotfinia M, Aghabarari A, et al. Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression. Molecular neurobiology. 2016;53(1):143-54. PubMed Epub 2014/11/25. Eng.
16. Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines. 2007;6(4):559-78. PubMed Epub 2007/08/03. eng.
17. Mancek-Keber M, Jerala R. Postulates for validating TLR4 agonists. Eur J Immunol. 2015;45(2):356-70. PubMed Epub 2014/12/06. eng.
18. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009;30(1):23-32. PubMed Epub 2008/12/09. eng.
19. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111-23. PubMed Epub 2010/07/29. eng.
20. Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471-86. PubMed Epub 2011/04/22. eng.
21. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood. 2012;120(15):3019-29. PubMed Pubmed Central PMCID: PMC3557399, Epub 2012/08/31. eng.
22. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009;182(4):2492-501. PubMed Epub 2009/02/10. eng.
23. Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol. 1998;161(7):3271-81. PubMed Epub 1998/10/06. eng.
24. Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf IG. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol. 2006;18(8):1279-83. PubMed Epub 2006/06/15. eng.
25. Ghaemi A, Soleimanjahi H, Gill P, Hassan ZM, Razeghi S, Fazeli M, et al. Protection of mice by a lambda-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology. 2011;54(3):105-12. PubMed Epub 2010/10/20. eng.
26. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198(2):267-79. PubMed Pubmed Central PMCID: PMC2194082, Epub 2003/07/23. eng.
27. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol. 2013;34(2):50-8. PubMed Pubmed Central PMCID: PMC3615427, Epub 2012/09/29. eng.
28. Kim D, Hung CF, Wu TC, Park YM. DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine. 2010;28(45):7297-305. PubMed Pubmed Central PMCID: PMC3150506, Epub 2010/09/08. eng.
29. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine. 2008;26(15):1807-16. PubMed Epub 2008/03/11. eng.
30. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, et al. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A. 2009;106(9):3330-5. PubMed Pubmed Central PMCID: PMC2651345, Epub 2009/02/13. eng.
31. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol. 2007;178(5):2853-61. PubMed Epub 2007/02/22. eng.
32. Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine. 2007;25(28):5189-98. PubMed Epub 2007/06/06. eng.
33. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest. 2004;114(12):1800-11. PubMed Pubmed Central PMCID: PMC535067, Epub 2004/12/16. eng.
34. Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine. 2008;26(46):5855-63. PubMed Pubmed Central PMCID: PMC2597163, Epub 2008/09/06. eng.
35. Mutwiri G, van Drunen Littel-van den Hurk S, Gerdts V, Auray G, Eng N, Garlapati S, et al. Combination adjuvants: the next generation of adjuvants? Expert Rev Vaccines. 2011;10(1):95-107. PubMed Epub 2010/12/18. eng.
36. Hermans IF, Silk JD, Gileadi U, Masri SH, Shepherd D, Farrand KJ, et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol. 2007;178(5):2721-9. PubMed Epub 2007/02/22. eng.
37. Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, Lee KM, et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther. 2011;18(9):898-909. PubMed Pubmed Central PMCID: PMC3169807, Epub 2011/04/01. eng.
38. Wang J, Kobayashi Y, Sato A, Kobayashi E, Murakami T. Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA. J Dermatol Sci. 2004;36(1):66-8. PubMed Epub 2004/10/19. eng.
39. Buferne M, Chasson L, Grange M, Mas A, Arnoux F, Bertuzzi M, et al. IFNgamma producing CD8 T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology. 2015;4(2):e974959. PubMed Pubmed Central PMCID: PMC4404920, Epub 2015/05/08. Eng.